BITES 和 CARS 和检查点，哦，我的！2018 年美国血液学会年会关于髓系恶性肿瘤免疫治疗的最新进展。
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
机构信息
Leukemia Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Leukemia Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA.
出版信息
Blood Rev. 2020 Sep;43:100654. doi: 10.1016/j.blre.2020.100654. Epub 2020 Jan 21.
Abstract
It is without question that immune checkpoint inhibitors and adoptive cellular therapies have revolutionized the treatment of solid and hematologic malignancies. Investigators are now developing novel strategies to integrate these groundbreaking modalities into the care of patients with acute myeloid leukemia (AML) and other myeloid malignancies. Here we provide an overview of the most recent developments in immunotherapy for myeloid cancers presented at the 2018 American Society of Hematology annual meeting. Topics discussed include adoptive cellular therapies (CAR-T, NK cell, and vaccines), checkpoint inhibitors, and bispecific T-cell engager (BITE) antibodies. Despite reservations regarding low antigenicity and having long been considered a "cold" tumor, immunotherapy remains a highly promising strategy for patients with aggressive myeloid cancers like myelodysplasia (MDS) and AML.
摘要
毫无疑问，免疫检查点抑制剂和过继性细胞疗法已经彻底改变了实体瘤和血液系统恶性肿瘤的治疗方式。研究人员正在开发新的策略，将这些开创性的治疗方法整合到急性髓系白血病（AML）和其他髓系恶性肿瘤患者的治疗中。在这里，我们提供了在 2018 年美国血液学会年会上展示的髓系癌症免疫治疗的最新进展概述。讨论的主题包括过继细胞疗法（CAR-T、NK 细胞和疫苗）、检查点抑制剂和双特异性 T 细胞衔接（BITE）抗体。尽管存在抗原性低的问题，并且长期以来一直被认为是一种“冷”肿瘤，但免疫疗法仍然是治疗侵袭性髓系癌症（如骨髓增生异常综合征和 AML）患者的极具前景的策略。
相似文献
1
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.BITES 和 CARS 和检查点，哦，我的！2018 年美国血液学会年会关于髓系恶性肿瘤免疫治疗的最新进展。
Blood Rev. 2020 Sep;43:100654. doi: 10.1016/j.blre.2020.100654. Epub 2020 Jan 21.
2
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?免疫疗法在急性髓系白血病和骨髓增生异常综合征中的应用：新时代的曙光？
Blood Rev. 2019 Mar;34:67-83. doi: 10.1016/j.blre.2018.12.001. Epub 2018 Dec 5.
3
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?免疫疗法治疗骨髓增生异常综合征和急性髓系白血病：我们处于什么阶段？
Expert Rev Hematol. 2023 Jul-Dec;16(11):819-834. doi: 10.1080/17474086.2023.2268273. Epub 2023 Nov 17.
4
Emerging Immunotherapy for Acute Myeloid Leukemia.急性髓系白血病的新兴免疫疗法。
Int J Mol Sci. 2021 Feb 16;22(4):1944. doi: 10.3390/ijms22041944.
5
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.免疫治疗急性髓细胞白血病的最新进展。
Blood Cancer Discov. 2024 Jul 1;5(4):234-248. doi: 10.1158/2643-3230.BCD-23-0202.
6
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.AML 和 MDS 中免疫疗法的最新进展：单克隆抗体和检查点抑制剂为临床实践铺平道路。
Adv Exp Med Biol. 2018;995:97-116. doi: 10.1007/978-3-030-02505-2_4.
7
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.利用免疫系统对抗白血病：急性髓系白血病的单克隆抗体与检查点策略
Adv Exp Med Biol. 2017;995:73-95. doi: 10.1007/978-3-319-53156-4_4.
8
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.小儿急性白血病现代治疗方法的见解
Cells. 2022 Jan 2;11(1):139. doi: 10.3390/cells11010139.
9
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.双特异性抗体在成人急性白血病免疫治疗中的应用：第65届美国血液学会2023年年会的最新进展
Expert Opin Biol Ther. 2024 Apr;24(4):221-223. doi: 10.1080/14712598.2024.2333793. Epub 2024 Mar 25.
10
[Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].[急性髓系白血病免疫治疗的最新进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):633-636. doi: 10.19746/j.cnki.issn1009-2137.2019.02.053.
引用本文的文献
1
Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4 T cells in MDS.检查点免疫疗法与骨髓增生异常综合征（MDS）中肿瘤抗原特异性CD4 T细胞的优先激活相关。
Blood Neoplasia. 2025 Apr 25;2(3):100106. doi: 10.1016/j.bneo.2025.100106. eCollection 2025 Aug.
2
Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia.盐酸组胺与低剂量白细胞介素-2在急性髓系白血病复发预防新领域中的应用
Ther Adv Hematol. 2025 Jun 28;16:20406207251351086. doi: 10.1177/20406207251351086. eCollection 2025.
3
T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.特异性识别 NKG2D 配体和 PD-L1 的分裂嵌合抗原受体 T 细胞在体内有效消除急性髓系白血病的同时，对单核细胞衍生细胞具有更好的选择性。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10189-10201. doi: 10.1007/s00432-023-04865-1. Epub 2023 Jun 3.
4
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis.急性髓系白血病中的免疫检查点抑制剂：一项荟萃分析
Front Oncol. 2022 Apr 21;12:882531. doi: 10.3389/fonc.2022.882531. eCollection 2022.
5
Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies.使用双特异性T细胞衔接抗体对间皮素阳性儿童急性髓细胞白血病进行免疫治疗靶向
Cancers (Basel). 2021 Nov 26;13(23):5964. doi: 10.3390/cancers13235964.
6
Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL.共表达GM-CSF/IFN-α/tWT1的诱导树突状细胞启动T细胞和B细胞以及用于增强移植物抗白血病效应的自动化生产
Mol Ther Methods Clin Dev. 2021 Apr 9;21:621-641. doi: 10.1016/j.omtm.2021.04.004. eCollection 2021 Jun 11.
7
Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.急性髓系白血病：从生物学通过研发和临床前治疗到临床实践
Front Oncol. 2020 Dec 9;10:599933. doi: 10.3389/fonc.2020.599933. eCollection 2020.
8
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development.急性髓系白血病的进展：近期获批疗法及研发中的药物
Cancers (Basel). 2020 Nov 1;12(11):3225. doi: 10.3390/cancers12113225.
本文引用的文献
1
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.派姆单抗联合地西他滨治疗难治性或复发急性髓系白血病。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003392.
2
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.B7-H3 特异性嵌合抗原受体 T 细胞治疗急性髓系白血病的临床前评估。
Clin Cancer Res. 2021 Jun 1;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 2.
3
New drugs for acute myeloid leukemia inspired by genomics and when to use them.基于基因组学的急性髓系白血病新药及其应用时机
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):45-50. doi: 10.1182/asheducation-2018.1.45.
4
Is the overall survival for older adults with AML finally improving?老年急性髓系白血病患者的总生存率终于有所提高了吗？
Best Pract Res Clin Haematol. 2018 Dec;31(4):387-390. doi: 10.1016/j.beha.2018.09.005. Epub 2018 Sep 20.
5
Advances in immunotherapy for acute myeloid leukemia.急性髓系白血病的免疫疗法进展。
Future Oncol. 2018 Apr;14(10):963-978. doi: 10.2217/fon-2017-0459. Epub 2018 Mar 15.
6
Redirecting T cells to hematological malignancies with bispecific antibodies.双特异性抗体引导 T 细胞靶向血液系统恶性肿瘤。
Blood. 2018 Jan 4;131(1):30-38. doi: 10.1182/blood-2017-06-741058. Epub 2017 Nov 8.
7
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性髓系白血病。
J Hematol Oncol. 2017 Aug 29;10(1):151. doi: 10.1186/s13045-017-0519-7.
8
Advances in Therapeutic Cancer Vaccines.治疗性癌症疫苗的进展。
Adv Immunol. 2016;130:191-249. doi: 10.1016/bs.ai.2015.12.001. Epub 2016 Jan 19.
9
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
10
Treating acute myeloid leukemia in older adults.治疗老年急性髓系白血病。
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):14-20. doi: 10.1182/asheducation-2014.1.14. Epub 2014 Nov 18.
Zotero 插件